Part 2/9:
On April 19, GW Pharmaceuticals received positive feedback from an FDA advisory committee regarding its drug, Epidiolex. This cannabinoid-based medication is under review for treating severe forms of childhood epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome. The advisory committee's unanimous vote in favor of the drug brings optimism for GW Pharmaceuticals, as historical data suggests that the FDA adopts committee recommendations in about 74% of cases.